v3.26.1
Revenue from contracts with customers (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue [abstract]  
Disclosures about major customers and credit risk
The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025

(€ million)EuropeUnited StatesOther
countries		June 30, 2026EuropeUnited
States		Other
countries		June 30, 2025
Total Group
4,304 11,633 6,169 22,106 4,144 9,535 6,210 19,889 
Immunology
of whichDupixent1,146 6,922 1,256 9,324 944 5,283 1,085 7,312 
Rare diseases
of which
ALTUVIIIO
— 576 98 674 — 456 86 542 
Fabrazyme
138 256 129 523 134 261 130 525 
Nexviazyme/Nexviadyme152 211 63 426 132 195 60 387 
Cerezyme126 86 140 352 119 91 153 363 
Ayvakit44 322 1 367 — — — — 
Oncology
of which
Sarclisa
108 132 114 354 83 119 74 276 
Other medicines
of whichLantus146 344 323 813 149 395 332 876 
Toujeo259 134 336 729 248 126 318 692 
Plavix40 2 398 440 44 3 426 473 
Lovenox202 5 157 364 247 9 191 447 
Rezurock36 218 42 296 23 220 20 263 
Industrial sales181 7 2 190 241 1 9 251 
Vaccines
of which
Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B
206 487 671 1,364 223 320 818 1,361 
RSV vaccines (Beyfortus)
87 65 240 392 85 68 203 356 
Meningitis, travel and endemics vaccines118 268 179 565 96 319 194 609 
COVID-19 and Influenza vaccines33 16 72 121 52 54 108 214 
Of which total launches
546 1,891 610 3,047 423 1,204 473 2,100 
Disclosure of other revenue
(€ million)
June 30, 2026 (6 months)
June 30, 2025 (6 months)
VaxServe sales of non-Sanofi products
746 842 
Sales to Opella (a)
60 61 
Royalties
91 68 
Other(b)
271 275 
Total Biopharma Other revenues
1,168 1,246 
Sales / Revenues from Opella products(c)
270 206 
Total Other revenues
1,438 1,452 
(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).
(b)    This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.
(c)    Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily